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ABSTRACT: Oligonucleotide-based agents have the potential to treat or cure almost any disease, and are one of the key therapeutic 
drug classes of the future. Bioconjugated oligonucleotides, a subset of this class, are emerging from basic research and being suc-
cessfully translated to the clinic. In this review, we first briefly describe two approaches for inhibiting specific genes using oligonu-
cleotides - antisense DNA (ASO) and RNA interference (RNAi) – followed by a discussion on delivery to cells. We then summarize 
and analyze recent developments in bioconjugated oligonucleotides including those possessing GalNAc, cell penetrating peptides, α-
tocopherol, aptamers, antibodies, cholesterol, squalene, fatty acids, or nucleolipids. These novel conjugates provide a means to en-
hance tissue targeting, cell internalization, endosomal escape, target binding specificity, resistance to nucleases, and more. We next 
describe those bioconjugated oligonucleotides approved for patient use or in clinical trials. Finally, we summarize the state of the 
field, describe current limitations, and discuss future prospects. Bioconjugation chemistry is at the centerpiece of this therapeutic 
oligonucleotide revolution, and significant opportunities exist for development of new modification chemistries, for mechanistic 
studies at the chemical-biology interface, and for translating such agents to the clinic.
INTRODUCTION
  
 The molecular biology central dogma describes the 
transfer of biological information stored in genes to proteins us-
ing biomacromolecules.1 The biomacromolecule deoxyribonu-
cleic acid (DNA) is found in all nucleated eukaryotic cells and 
it stores information via a specific sequence present in DNA. 
The first-step in this unidirectional process of genes to proteins 
is transcription whereby ribonucleic acid (RNA) is generated 
from DNA (i.e., transcription). RNA is then spliced into the nu-
cleus to retain only the coding part of the RNA, namely the ex-
ons. The resulting messenger RNA (mRNA) is transferred to 
the cytoplasm, where the ribosome reads the information and 
produces a protein (i.e., translation). These biomacromolecules 
play key roles in all aspects of life from life cycle, pathogenesis, 
to healing and, thus, opportunities exist to control a biological 
outcome by intervening in transcription or translation. 
In 1967, synthetic nucleoside derivatives were re-
ported with the intent for specific base pairing with target se-
quences2. In 1978, Summerton developed methods for inacti-
vating sequences through crosslinking3, and Zamecnik and Ste-
phenson4,5 reported that short synthetic DNA fragments (called 
oligodeoxynucleotides, ODN) from the Rous sarcoma virus, 
possessing sequence binding complementary to RNA mole-
cules, inhibited viral replication. This seminal discovery docu-
mented replication prevention of a viral RNA strain using a spe-
cific ODN - today known as antisense treatment6. Several stud-
ies have also elucidated many of the molecular mechanisms un-
derlying different human and animal pathologies. Thus, altering 
the expression of pathological genes, whether genetic or modi-
fied by mutation, is of keen interest and technologies are being 
developed for such purposes. 
Antisense DNA (ASO) and RNA interference (RNAi) 
are two very promising technologies for inhibiting specific 
genes. The former utilizes a DNA fragment complementary to 
the target mRNA sequence. The latter approach, first described 
by R. Jorgensen7 and extensively studied by Andrew Z. Fire and 
Craig Mello,8 uses small interfering RNAs (siRNAs) to target 
the mRNA. Antisense oligonucleotides induce different inhibi-
tion mechanisms, which can occur in the cytoplasm and in the 
nucleus (Figure 1). After transcription of the DNA into pre-
messenger RNA, several post-transcriptional modifications are 
performed, including splicing, capping at the 5' end, or the pol-
yadenylation of the 3' end. The mRNA is then translocated into 
the cytoplasm by exportins, where it is then translated into pro-
teins by ribosomes. A synthetic oligonucleotide elicits its activ-
ity in two cellular compartments, the cytoplasm or the nucleus. 
After hybridization of the oligonucleotide on mRNA, two in-
hibitory mechanisms are possible: i) mRNA degradation or ii) 
translational repression. mRNA is degraded upon hybridization 
with an oligonucleotide following RNase H recognition. Anti-
sense DNA can also inhibit the translation step via a steric hin-
 drance mechanism at the ribosome binding site9 or by prohibit-
ing the ribosomal motion along the mRNA.10,11 Several mecha-
nisms of inhibition are also possible in the nucleus, including 
the inhibition of post-transcriptional modifications, such as cap-
ping at the 5' end, or by binding to polyadenylation sites at the 
3' UTR ends.12,13 Additionally, antisense may also inhibit or 
promote the inclusion of exons to alter the splicing of pre-
mRNA (Figure 1). 
In principle, protein regulation is accomplished by the 
use of either agonist14,15 or antagonist16–18 strategies, with the 
caveat that the target RNA sequence is known. Because they are 
exogenous molecules, synthetic oligonucleotides are substrates 
for endo- and exo-nucleases, and thus exhibit short half-lives 
both in vitro and in vivo. For example, after intravenous (IV) 
injection in monkeys, phosphodiester oligonucleotide ana-
logues are quickly degraded with a half-life of only 5 minutes.19 
In order to overcome this low stability, oligonucleotides are 
chemically modified. Sites of chemical modification include the 
base, ribose, and the phosphate linkage. The types of modifica-
tions vary from classical to non-classical bioisosteres.20 Addi-
tionally, one chemical modifications does not always address 
the same half-life limitation(s), and often two or more modifi-
cations are combined to increase oligonucleotide stability. Dur-
ing the last few decades, many different modification chemis-
tries have been developed (Figure 2). One of the first chemical 
modifications reported is the replacement of the phosphodiester 
by a phosphorothioate linkage (PTO) to minimize oligonucleo-
tide degradation. Interestingly, this modification does not inter-
fere with the recruitment of RNase H and target RNA cleavage. 
Structures of the different chemical modifications and the 
knockdown mechanisms are shown in Figure 2.21–26 To improve 
the binding affinity and nuclease resistance, chemical modifi-
cations including the 2’-O-methyl (2’-OMe), 2′-O-methoxy-
ethyl (2′-MOE), and/or 2’-fluoro (2’-F) modifications of RNA 
are inserted into the structure. To enhance the binding affinity, 
Locked nucleic acid (LNA) modifications are used where the 
conformational freedom of the ribose is restricted. More re-
cently, Tricyclo-DNA (tcDNA) are reported as another con-
strained nucleotide featuring a three-ring scaffold. Importantly, 
these types of chemical modifications efficiently address the 
degradation issues. However, they do not improve the cellular 
uptake or targeting of the oligonucleotide to a specific site at the 
cellular, tissue, or organ level. Indeed, these hydrophilic poly-
anions do not easily cross a physiologic barrier (e.g., skin) or a 
cell membrane.  
 
Figure 1: Mechanisms of antisense oligonucleotides (adapted 
from Chan J. H. P. et al. 2006 12) Normal expression of the gene 
and protein in the absence of ASO (1). After internalization, ASO 
hybridize to mRNA via complementary sequence pairing. The 
ASO/mRNA heteroduplex induces activation of RNase H and de-
gradation of the mRNA (2) or ribosome blockage by steric hin-
drance (3). Both mechanisms result in inhibition of target protein 
production. Alternatively, penetration of ASO into the nucleus 
may lead to regulation of mRNA via inhibition of capping forma-
tion at the 5’ end (4), inhibition of splicing (5) or the activation of 
RNase H (6). 
 
 
Figure 2: Chemical modifications of synthetic oligonucleotides 
(Adapted from Khvorova A. and Watts J. K. 2017 21) Chemical 
modifications are incorporated at the phosphate, ribose or at the 5’ 
or 3’ ends of the oligonucleotides. The type and the position of the 
modification induce three main mechanisms (steric blockers in 
green, activation of RNase H in blue and RNA interference (RNAi) 
in orange). In the case of 2’ modification (2’-OMe, 2’-O-MOE, 
2’NH2, 2’-F-RNA and 2’-F-ANA), RNase H and RNAi me-
chanism are possible with a gapmer design. 
PTO: Phosphorothioate ; CNA : Dioxaphosphorinane-Constrai-
ned Nucleic Acid ; PNA : Peptide Nucleic Acid ; PMO : Phospho-
rodiamidate Morpholino Oligonucleotide ; E-VP : (E)-VinylPhos-
phonate ; ddC : dideoxyCytosine ; 2’-OMe : 2’ O-Methyl ;2’-O-
MOE :  2’-O-MethOxy Ethyl ; 2’-F RNA; 2’-F ANA : ArabinoNu-
cleic Acid ; LNA : Locked Nucleic Acid ; ENA :  2’-O,4’-C-Ethy-
lene-bridged Nucleic Acid ; cEt : S-constrained Ethyl ; tcDNA : 
tricycloDNA ; FHNA : Fluoro Hexitol Nucleic Acid ; UNA : 
Unlocked Nucleic Acid. 
 Therapies must adhere to a wide range of stringent 
specifications in order to advance into clinical trials and suc-
ceed. An ideal oligonucleotide therapy is safe to administer, af-
fordable to produce, exhibits a 2 year shelf-life, possesses an 
extended half-life in blood and serum (> 12 hrs), and inhibits 
intended targets effectively with low nonspecific or off-target 
interactions.27 That said, differing disease indications will re-
quire fine tuning of the design requirements for optimal perfor-
mance. As discussed below, a wide range of modifications to 
oligonucleotides improve one or many of these parameters, and 
the use of bioconjugation to oligonucleotides is primarily fo-
cused on improving the delivery of oligonucleotides to the cy-
tosol or nucleus. Bioconjugates address a number of different 
oligonucleotide delivery challenges, such as improving biodis-
tribution to a specific region or cell type (e.g., antibodies), pro-
moting endosomal escape (e.g., CPP), increasing receptor-me-
diated transport (e.g., GalNAc), and/or increasing lipophilicity 
(e.g., cholesterol). 
 In this review, we discuss recent advances in the de-
livery of oligonucleotides. We briefly describe self-assembly 
approaches based on electrostatic, hydrophobic, or H-bonding 
interactions to give, for example, lipoplexes, and refer the 
reader to several comprehensive reviews on this topic.28,29 We 
focus on modified bioconjugated oligonucleotides for delivery, 
including GalNAc, cell penetrating peptides, α-tocopherol, ap-
tamers, antibodies, cholesterol, squalene, fatty acids, nucleoli-
pids, and bis-conjugates. We also describe relevant linking 
chemistries between the oligonucleotide and the bioconjugate 
with respect to molecular design.. Additionally, the therapeutic 
applications of such bioconjugated oligonucleotides and out-
comes from clinical trials are highlighted. Finally, we summa-
rize the state of the field and discuss future prospects. Today, 
significant opportunities exist for development of new modifi-
cation chemistries, for mechanistic studies at the chemical-biol-
ogy interface, and for engineering systems for efficient delivery 
to the target site. 
 
OLIGONUCLEOTIDE DELIVERY 
Cellular uptake is one of the key steps in order for ol-
igonucleotides to elicit their biological activity, as the target 
mRNAs and the cellular machinery are located in the cytoplasm 
and in the nucleus. Several transfection agents have been devel-
oped and commercialized for the intracellular delivery of oligo-
nucleotides such as oligofectamine 2000 (Invitrogen), JetPEI 
(Polyplus transfection) or K2 (Biontex). Many of these trans-
fecting products are composed of cationic lipids, polyethyl-
enimine, or DEAE-dextran, which self-organize and self-as-
semble in aqueous medium via electrostatic interactions with 
the negatively charged oligonucleotides. This strategy com-
pacts the oligonucleotide into aggregates for subsequent endo-
cytosis by the cell. Once inside the cell, the oligonucleotides are 
released into the cytoplasm. However, toxicity remains a disad-
vantage of these agents, as most of transfecting agents are cati-
onic, but alternatives are being investigated.30,31 Additionally, 
many of these complexes are not stable in the presence of se-
rum, limiting or preventing their in vivo use.32,33 Following in-
travenous administration, the resultant oligonucleotide/trans-
fecting agent complexes accumulate primarily in the liver, due 
to their size.34 Consequently, significant research efforts are 
dedicated to the delivery challenges in order to improve the 
transfection of nucleic acids.35–37 For example, poly(2-dime-
thylaminoethyl) methacrylate, when mixed with oligonucleo-
tides,38 forms micelles of controlled sizes based on the N/P ra-
tio. Upon adding an albumin coating to the surface, the cyto-
toxic effect of the polymer is minimized and cancerous cells are 
preferentially transfected relative to healthy cells.39 Another 
strategy employs modified viruses, which internalize nucleic 
acids in cells.40–42 However, this strategy can afford off-target 
toxicity since the oligonucleotides are not delivered in their syn-
thetic form, but rather integrated into the viral genome. Lipid 
nanoparticles (LNP) are also being investigated as the non-viral 
transfecting cargo. However, the transfection efficiency is gen-
erally lower than that observed for viral transfection systems.43  
Recently, LNPs loaded with siRNA targeting Polo-
Like Kinase 1 (PLK1) protein, present in the triple negative 
breast cancer cell line (MDA-MB-231), have been modified 
with antibodies to target tumors. Biodistribution studies of la-
beled siRNA-LNPs demonstrated that antibody modified LNP 
(antibody against heparin-binding EGF-like growth factor, 
αHB-EGF) effectively delivered siRNA to tumor tissue in mice. 
Interestingly, the PLK1 protein expression was inhibited after 
intravenous injection of the LNPs and tumor growth was de-
creased. These results indicate that antibody modified LNPs 
loaded with siRNA are a promising therapeutic approach for 
breast cancer.44 Another recent article investigated the biocon-
jugation of antibodies to LNP for targeting endothelial cells lin-
ing the vascular lumen.45,46 These new particles were non toxic 
both in vitro and in vivo as well as preferentially accumulated in the 
lungs. In contrast, the same nanoparticles without conjugated anti-
bodies quickly accumulated into the liver, indicating that targeting 
moieties (antibodies/LNP bioconjugate) can avoid the hepatic up-
take with endogenous serum protein like Apo-E.47 
Alternatively, bioinspired molecules such as nucleoli-
pids (NL) are being used to construct LNPs. NLs self-assemble 
to form unique supramolecular structures,48–52 and the LNPs 
based NLs loaded with nucleic acids successfully transfect plas-
mid DNA, siRNA, and antisense oligonucleotides to a number 
 
Figure 3: Strategies for the delivery of ASO and/or siRNA. Adapted 
from Järver et al. 2012 57 A: Formation of a complex between a bio-
molecule or a polymer and the oligonucleotide via electrostatic in-
teractions and / or the hydrophobic effect, B: Formation of liposomal 
supramolecular structure with targeting or transfecting agent (PEG, 
peptide, CPP, protein, lipid glycoconjugate, etc.), C: Covalent con-
jugation with the oligonucleotide by a stable or cleavable bond. 
 of different cell lines: human breast adenocarcinoma MCF-7 
cells, human liver (HepG2), mouse fibroblast (NIH 3T3), Chi-
nese hamster ovarian (CHO) cells, and human prostate cancer 
(PC-3) cells.51,53–55 Furthermore, these LNPs can be further 
modified to be stimuli-responsive, such as responding to 
changes in pH to enhance the delivery of nucleic acids.56 The 
above examples are representative and by no means compre-
hensive, as there are many formulations described for nucleic 
acid vectorization (Figure 3), and the reader is referred to sev-
eral comprehensive reviews on the subject.57,58  
The re-targeting of nucleic acids using viral vectors 
was investigated by Reynolds et al. in the 2000’s.59,60 Viral vec-
tors are attractive candidates for in vivo gene delivery because 
the infection efficacy is higher compared to other non-vial ap-
proaches. For example an adenovirus vector was prepared con-
taining both a Fab fragment of an anti-Ad5 knob antibody and 
the anti-ACE monoclonal antibody mAb 9B9. This bi-specific 
conjugate exhibited enhanced pulmonary distribution by a syn-
ergic effect (transductional and transcriptional).59,60 The major 
drawback of using this vector is sequestration by Kupffer cells 
into liver tissue. 
 
BIOCONJUGATED OLIGONUCLEOTIDE DELIVERY 
The conjugation of specific molecules to oligonucleo-
tides is a promising therapeutic approach for nucleic acid based 
drugs. Consequently, bioconjugates are of increasing presence 
in the pharmaceutical development pipeline. The major ad-
vantages of working with a bioconjugate include: 1) a new 
chemical entity; 2) of defined composition; and, 3) synthesized 
using chemical methods as opposed to bioprocesses. These at-
tributes, unlike formulations with polymers or other transfect-
ing reagents61 that give heterogeneous mixtures requiring ex-
tensive multi-pronged characterization analyses, will facilitate 
translation to the clinic. Additionally, these covalently conju-
gated molecules play one or more roles in recognition, targeting 
of cells or tissues, cellular internalization, and pharmacokinet-
ics. 
The review of covalently conjugated oligonucleotides 
necessitates discussion on appropriate and effective linkers and 
linking chemistries, as interference strategies can be stymied by 
functionalization(s)62. Both cleavable and stable linkers are suc-
cessfully used. Bio-orthogonal “click” chemistry approaches 
such as akyne-azide, and thio-maleimide are two common ap-
proaches to form stable linkages with highly specific reactions. 
Cleavable bonds such as reducible disulfide linkages, esters 
(cleavable through hydrolysis or esterases), phosphodiesters 
(cleavable through nucleases) and peptides (cleavable through 
proteases) are also being utilized and examples are discussed 
below. Additionally, alternatives such as end functionalization 
(5’ or 3’), and other cleavable strategies will be discussed in the 
context of different conjugated moieties.  
PEG modification. Poly(ethylene glycol) (PEG) was 
first conjugated to oligonucleotides more than two decades ago 
by different academic groups, including Bonora,63 and Bur-
covich64 in order to improve stability, avoid rapid degradation, 
and enhance cellular uptake.65 In 2003, Ji Hoon Jeong et al. de-
scribed PEG attached to an antisense oligonucleotide sequence 
(c-myb) to afford a surrounding corona, which would prohibit 
interactions with plasma proteins and increase aqueous solubil-
ity.66 Intracellular uptake is achieved due to the formation of a 
micellar system resulting from the combination of PEG conju-
gates with fusogenic cationic peptides. These formulations ex-
hibit higher antiproliferative activity against smooth muscle 
cells compared to the unconjugated c-myb antisense. 
GalNAc modification. The GalNAc (N-acetylgalac-
tosamine) modification, introduced by Nair et al., lead to hy-
drophilic glycoconjugates67 (Figure 4), increasing the cellular 
internalization in the liver due to binding to the ASialoGlyco-
Protein Receptor (ASGPR). These lectin type C receptors are 
highly expressed on the plasma membrane of hepatocytes and 
both galactose and GalNAc are the preferred ligands for these 
receptors. After binding to ASGPR, the complex is quickly in-
ternalized to form early endosomes via a clathrin dependent 
mechanism.68 As a result, ASGPR targeting conjugates are 
readily delivered to the liver through intraveneous injection. 
Once inside the cell, the oligonucleotides must escape 
from the endosome intact to elicit their bioactivity. At neutral 
pH, the dissociation constant between these modified oligonu-
cleotides and their receptor is very low (Kd in the nanomolar 
 
Figure 4: Molecular structures of GalNAc based conjugates, adapted 
from Matsuda et al. 2015 72 Diagram showing an oligonucleotide 
coupled to GalNAc (left) and molecular structure (right). The trian-
tennular GalNAc is represented in the upper part, the GalNAc incor-
porated in sequence in the lower part. 
 
  
Figure 5: Cellular internalisation of GalNAc oligonucleotide conju-
gates, adapted from Alnylam. The GalNAc moiety is a ligand of the 
ASGPR receptors. The formation of the complex induces a clathrin-
dependent endocytosis mechanism. Acidification dissociates the 
siRNA-releasing substrate / receptor complex (3) into the cytoplasm 
(4). RNAi-mediated degradation of the targeted mRNA mechanism 
(5). Inhibition of protein translation (6). ASGPR receptors are re-
cycled in the plasma membrane (7). 
 
 range), indicating a strong association with ASGPR receptors. 
Once inside the endosome, the acidic pH allows for dissociation 
of the ligand-receptor complex, resulting in the return of 
ASGPR to the membrane (Figure 5) and subsequent release of 
the ligand. The GalNAc modification facilitates cell internali-
zation. Finally, the GalNAc modified oligonucleotides escape 
the endosome.69 
To prepare these bioconjugates, the GalNAc modifi-
cation is introduced into the oligonucleotide either during DNA 
synthesis as a non-nucleoside monomer or at the end of the oli-
gonucleotide synthesis as a "triantennular" form (Figure 4). The 
synthesis of such oligonucleotide conjugates is compatible with 
standard automated solid phase synthesis, where the GalNac 
modification is attached either at the 3', 5' extremities or within 
the oligonucleotide sequence.70 The non-nucleoside monomer 
is attached through a phosphodiester linkage during oligonucle-
otide synthesis as a synthetic phophoramidite. All of the differ-
ent chemical modifications (2'-OMe, 2'-F, PTO), which can be 
inserted within the same sequence, are compatible with the Gal-
Nac conjugation approach. Manoharan et al reported that these 
modifications improve the in vivo stability of siRNA−GalNAc 
conjugates.67 Interestingly, after subcutaneous injection, the 
siRNA−GalNAc conjugates distribute to the liver with subse-
quent gene expression decrease of the targeted mRNA, thus en-
abling this approach for treating a wide range of liver dis-
eases.71,72 The pharmacokinetics of GalNAc-siRNA conjugates 
were evaluated in monkeys73 and it was found that phos-
phorothioate linkages in the 5’-region of siRNA−GalNAc 
strands minimally affect plasma pharmacokinetics but result in 
a greater liver exposure. This provides a prolonged duration of 
gene silencing due to improved metabolic stability. The tech-
nology was also developed for ASOs targeting apolipoprotein 
with a successful improvement (10-fold) of inhibition effect in 
vivo.74,75 In this study, the active ASO is liberated only after in-
ternalization into cells and not in the plasma, demonstrating that 
ASO-GalNac conjugates are a functional prodrug. Many Gal-
NAc conjugated oligonucleotides are currently in preclinical 
and clinical trials.76 For example, Fitusiran77,78 is a siRNA de-
veloped by Alnylam for the treatment of hemophilias. The col-
laboration between Ionis and Akcea yielded ASO IONIS-APO 
(a) LRX for the treatment of hyperlipoproteinemia and cardio-
vascular diseases. Additionally, two anti-miRNAs are being de-
veloped by Regulus to treat viral diseases, such as hepatitis C 
(RG-101), and a third is being developed in collaboration with 
AstraZeneca for the treatment of type 2 diabetes (RG-125).76 
Peptide Sequences: Cell Penetrating Peptide (CPP) 
and RGD. CPPs are short peptidic sequences, generally not ex-
ceeding thirty residues, which possess the ability to cross a cel-
lular membrane and facilitate endosomal escape (Figure 6). 
CPP are classified into three categories: 1) protein-derived pep-
tides; 2) chimeric peptides formed by the fusion of two natural 
sequences; and, 3) synthetic peptides based on structure/func-
tion studies.79 These short peptides are ligands for specific re-
ceptors that facilitate cell internalization by endocytosis and de-
stabilization of endosomes compartments. For example, Lönn 
et al. speculated that the PTD/CPP-EED domains enhance cel-
lular delivery by insertion of a hydrophobic patch into the lipid 
bilayer at a critical distance (18 bonds) from the delivery do-
main. This resulting concentration in the endosome results in a 
strong localized membrane destabilization leading to enhanced 
escape into the cytoplasm.80 All CPPs do not exhibit the same 
penetration mechanism, membrane leakage rates, or toxicity. In 
2007, a CPP ((RXR)4 (X = 6-aminohexanoic acid)) conjugated 
to a PMO oligomer was investigated.81 The CPP-PMO conju-
gates did not show toxicity below a dose of 15 mg/kg after in-
travenous injection (bolus). However at a dose of 30 mg/kg, an-
imal body weight decreased while at a dose of 150 mg/kg, the 
animals were lethargic with elevated levels of creatinine. Blood 
biochemisty analysis of albumin, electrolytes, and bilirubin 
showed constant levels at all doses.81  
A major design issue for these conjugates is the com-
plexation between the anionic oligonucleotides and the cationic 
CPPs. In a previous review, Steven Dowdy focused on the po-
tential use of CPP to deliver siRNA, and the reader is referred 
to this manuscript.82 The endocytosis-mediated uptake of such 
peptides depends on three important steps: cell association, in-
ternalization, and finally endosomal escape. Dowdy et al. also 
discuss the array of different cargos that have been delivered by 
cationic PTDs/CPPs as well as cellular processes and biological 
responses that have been modulated. CPPs share many common 
features responsible for efficient activity including positive 
amino acids (arginine and lysine) and hydrophobic residues 
(tryptophan and phenylalanine).83,84 Alternatively, non-ionic ol-
igonucleotides (PMO, PNA, phosphoryl guanidine) are good 
candidates to bypass this charge-charge complexation require-
ment. Such systems are used successfully for exon skipping.85–
87 Conventional formulations that carry oligonucleotides are 
composed of CPP via physical mixing, but the conjugation of 
these molecules to the oligonucleotide by a covalent bond pro-
vides additional benefits. The chemical insertion of multiple 
peptides on the same oligonucleotide improves the sensitivity 
of the conjugate for its receptor. In the case of siRNA conju-
gated to cyclic RGD, the internalization mechanism is achieved 
 
Figure 6: CPP grafting strategy on siRNA. A: Noncleavable 
oligonucleotide CPP conjugate. B: Representation of the cleavable 
conjugate by reduction of the disulfide bridge: (1) Bioconjugate en-
ters into the cell thanks to CPP. (2) Cleavage of the disulfide bridge 
allows detachment of the siRNA from the CPP moiety. (3) CPP enters 
into the nucleus. (4) siRNA elicits its inhibitory activity by an RNAi 
mechanism. Adapted with permission from Ye, J., Liu, E., Gong, J., 
Wang, J., Huang, Y., He, H., and Yang, V. C. (2017) High-Yield 
Synthesis of Monomeric LMWP(CPP)-SiRNA Covalent Conjugate 
for Effective Cytosolic Delivery of SiRNA. Theranostics 7, 
2495−2508.83 Copyright 2017, Ivyspring. 
 by caveola-dependent endocytosis.88,89 In another study, the 
bombesin peptide, coupled to the 5’ end of a splice-shifting ol-
igonucleotide (SSO), corrects splicing of an aberrant intron. 
This fourteen amino acid peptide, which is a neurotransmitter 
acting on the G protein receptors, facilitates oligonucleotide de-
livery to the nucleus of transfected prostate cancer PC3 cells.90–
92 Ye et al.83 demonstrated that a 3’ CPP covalently conjugated 
to siRNA increased their intra cellular delivery (Figure 6). The 
report investigated CPPs with different conjugation chemistries 
with a PEG space, one cleavable disulfide linkage, and another 
through a thiol-maleimide coupling. The incorporation of a sta-
ble versus cleavable linkage led to differences in knockdown 
and efficacy. 
The linear tripeptide RGD and its cyclic-RGD analogs 
are well known peptides for cell targeting. These peptide lig-
ands bind αvβ3 integrins which are overexpressed in several 
cancers, including melanomas,93 ovarian cancer,94 and breast 
cancer as well as in metastasis.95 Grafting such ligands to ther-
apeutic oligonucleotides provides a means for targeting and ef-
ficient delivery. However, a drawback of using the RGD as a 
targeting moiety is that the αvβ3 integrin is expressed on many 
cell types as well as platelets, and, as such off-target effects and 
toxicities are of concern. Although this class of peptide-modi-
fied bioconjugates is being actively investigated for the delivery 
of nucleic acid in vitro, positive results still remain to be con-
firmed in vivo. Additionally, biodistribution and resistance to 
proteolytic degradation are not reported. 
α-Tocopherol. α-Tocopherol, commonly known as 
vitamin E, is used for the treatment of hypercholesterolemia. 
This liposoluble moiety is often coupled to oligonucleotides to 
facilitate cell membrane interactions.96 For example, Yutaro 
Asami et al. coupled tocopherol to a siRNA at the 5' end of the 
29-nucleotide antisense strand for reducing apolipoprotein B 
(ApoB) levels. Improved inhibitory activity is observed relative 
to the parent cholesterol derivative. In fact, only 2 mg/kg is 
needed to significantly reduce ApoB mRNA in mouse liver af-
ter intravenous injection. In similar conditions, the amount of 
cholesterol conjugate required to observe the same activity was 
50 to 100 mg/kg.97 Additionally, α-tocopherol, coupled to an 
ASO, increases endogenous gene inhibition in a mouse liver 
compared to an unconjugated ASO.98 Simply conjugating to-
copherol to the oligonucleotide structure did not induce an in-
hibitory effect, and a spacer of several (4-7) Unlocked Nucleic 
Acids (UNA) was required between the oligonucleotide 5’ex-
tremity and tocopherol to maintain biological activity. In this 
study, the oligonucleotides within the ASO selected were Gap-
mers, oligonucleotides containing a mixture of chemically mod-
ified nucleotides (LNA, 2’-O-MOE, for example) at each ex-
tremities and a central sequence of DNA (the “gap”), allowing 
the RNase H cleavage after forming the mRNA/DNA comple-
mentary heteroduplex. The UNA residues, on the spacer, are 
cleaved in the cell affording the ASO using the RNase H mech-
anism for inhibition of mRNA. The inhibitory efficacy in-
creased by 3.5 fold compared to the intravenous injection of 
non-conjugated oligonucleotides. Importantly, tocopherol im-
proved the pharmacokinetics of ASO affording accumulation in 
the liver (9- -
after injection at a dose of 3 mg/Kg for the conjugated and un-
conjugated ASO, respectively), unlike the unconjugated ASO, 
which distributed primarily to the kidneys (1-2 μg/g and 12-16 
μg/g were found in the kidneys 6 h after injection at a dose of 3 
mg/Kg for conjugated and unconjugated ASO, respectively). 
Aptamers. Aptamers are oligonucleotide sequences 
(DNA or RNA) possessing a three-dimensional structure for bi-
ological recognition. Using a method called SELEX (System-
atic Evolution of Ligands by EXponential enrichment) specific 
oligonucleotides are identified that bind a target with high af-
finity (Kd in the range of nanomolar to picomolar). Sullenger et 
al.99 used this approach to select an aptamer capable of targeting 
the Prostate-Specific Membrane Antigen (PSMA) receptor at 
the surface of prostate cells. The designed RNA molecule con-
tained both the aptamer and siRNA moieties. This chimeric ap-
tamer-siRNA features a dsRNA (siRNA) motif that is a sub-
strate for the intracellular Dicer enzyme, an endoribonuclease. 
As a proof of concept, LNCaP and PC-3 prostate cells were 
treated with the chimeric aptamer-siRNA containing a thera-
peutic siRNA sequence that targets genes overexpressed in hu-
man tumors (PLK1 and BCL2). Successful knockdown resulted 
in a decrease in cell proliferation and an increase in apoptosis. 
As a control, an aptamer chimera bearing two point mutations 
exhibited an absence of specificity for its target, indicating the 
specific binding between the aptamer and its receptor. In an-
other study, a siRNA targeting the tat/rev viral genes was con-
jugated via a short polynucleotide link to an aptamer that rec-
ognizes the glycoprotein gp120 of the HIV viral envelope. This 
conjugate suppressed HIV infection in human cell lines and in 
humanized mouse models.100–102 Aptamer-siRNA chimeras are 
of significant interest and the reader is referred to a recent re-
view summarizing the state-of-the-art.103 The additional ad-
vantages of such chimeras include lower production costs, low 
batch-to-batch variation, longer shelf-life and little-to-no im-
munogenicity and toxicity compared to antibody conjugates 
(discussed below).  
Given that the three-dimensional structure is required 
for recognition and that aptamers are degraded by nucleases, 
significant research efforts are directed at modifying nucleo-
tides to increase the stability without losing target recognition. 
There are several locations and types of modifications being in-
vestigated including: the terminals of nucleic acids, the phos-
phodiester linkage, the sugar ring and modifications on the ba-
ses, as well as 3’ end capping with inverted thymidine and PEG 
conjugation.104 
Antibodies. Monoclonal antibodies are known for 
their recognition properties of biological targets. In 2005 
Lieberman et al.105 reported the use of a monoclonal antibody 
conjugate for the delivery of siRNA in order to inhibit the pro-
tein production of HIV. The antibody was conjugated to the 
ASO oligonucleotide via a click reaction involving an azide-
modified antibody and a cyclooctyne ASO. This strategy was 
further developed by Satake et al.106 to conjugate the anti-CD22 
antibody to the MXD3 oligonucleotide. This oligonucleotide 
targets a dimeric protein (MXD3) associated with MYC, a tran-
scription factor responsible for the survival of B cell precursor 
cells in acute lymphoblastic leukemia. The conjugate induces 
inactivation of the MXD3 protein responsible for apoptosis in 
vitro in leukemic cells as well as affords cytotoxicity in normal 
B cells but not in hematopoietic cells, including stem cells. The 
in vivo results are promising as only a dose of 0.2 mg/kg twice 
a week for 3 weeks is required to double survival (median 42.5 
vs. 20.5 days). Based on these encouraging results, antibody-
ASO conjugates are a new therapeutic option to decrease the 
doses and to favor the accumulation of ASOs at designated lo-
cations. However, the selection of antibody or antibody frag-
ment for targeting a specific cell type is challenging. For exam-
ple, Genentech published an article describing the investigation 
 of antibodies conjugated to ASO by a maleimide linkage, for 
targeting prostate carcinoma cells after systemic administra-
tion.101 This challenge is further complicated by the fact that the 
route of antigen internalization also affects silencing. Although 
antibody conjugates reach the intended target site, the subse-
quent steps of cellular internalization and endosomal escape are 
also required for efficacy.107 
Cholesterol. Lipid moieties, and particularly choles-
terol derivatives, are often conjugated to oligonucleotides for 
delivery purposes (Figure 7). Oligonucleotides modified with 
cholesterol are recognized by high and low-density lipoproteins 
(HDL and LDL) in vivo and internalized via cholesterol binding 
receptors. After intravenous or intraperitoneal injection, these 
oligonucleotide conjugates escape renal clearance, thus greatly 
impacting their pharmacokinetics by extending the time that the 
nucleic acids remain in the plasma. A number of studies have 
demonstrated the advantage of coupling a cholesterol moiety to 
the oligonucleotide in order to reduce its renal clearance. Also, 
cholesterol conjugation increases cellular uptake of oligonucle-
otides. Godeau et al. reported improved in vitro cellular inter-
nalization of an oligonucleotide functionalized with cholesterol 
via a "click chemistry" approach. Additionally, these conjugates 
inhibited viral translation of hepatitis via an IRES blocking 
mechanism.108 Additional studies in the KB-8-5 cell line 
showed that the cholesterol moiety allows endosomal escape 
without the use of any additional transfecting reagents. After 4 
hours, the siRNA conjugates accumulate in the intercellular 
space. After 24 hours, the distribution became homogeneous 
with an accumulation of the oligonucleotides in the cytoplasm 
of the cells.109,110 
From a design perspective, the spacer between the ol-
igonucleotide and cholesterol is crucial to maintain the biologi-
cal activity. Directly grafting the cholesterol to the 5' oligonu-
cleotide end reduced the inhibitory activity of the nucleic acids 
(siRNA or ASO).109,111 In another study, ApoB was targeted to 
the liver after a daily intravenous injection of siRNA-choles-
terol conjugates at a dose of 50 mg/kg.112 Additionally, the Hun-
tingtin protein was inhibited after a single intrastriatal injection 
of a cholesterol-coupled siRNA. These two examples demon-
strate that siRNA-cholesterol conjugation improves the delivery 
into different cell types other than liver cells.113 A photo-respon-
sive cholesterol-siRNA conjugate (on both sense or antisense 
strands) is recently reported containing a photo-cleavable link-
age (Figure 7)114. The orthonitrobenzyl group photo-cleaves in 
response to 365 nm UV light to yield the native 5’ end. Three 
different cholesterol derivatives were prepared to inhibit 3 dif-
ferent genes (2 exogenous, luciferase and GFP; and an endoge-
nous, Eg5) in hepatocarcinoma HepG2 cells. In the absence of 
light, this conjugation allows the internalization of the am-
phiphilic cholesterol-siRNA without inhibiting the target. In the 
presence of a light stimulus, the link between the cholesterol 
and the siRNA is cleaved, and the inhibitory activity of siRNA 
is introduced.111 
 Cholesterol is conjugated to oligonucleotides at dif-
ferent locations including the 5' or 3' end, as well as within the 
sequence. A recent study reported six constructs conjugated 
with cholesterol covalently bound either at the ends or after thy-
midines within the sequence. The oligonucleotide selected was 
a Gapmer with 2 and 3 LNAs at both the 5' and 3’ ends, respec-
tively. Higher in vitro activities are obtained when the choles-
terol is inserted either at the 5' end or within the sequence. In 
vivo, the cholesterol conjugates accumulate in the liver inde-
pendent of the lipid conjugation location (3’, 5’-ends or within 
the sequence). Furthermore, a regular phosphodiester linkage 
exhibited superior in vivo performance in terms of biological 
activity (by a factor of 5) compared to the analog phosphorothi-
oate as a link between the lipid and the ASO. Nakajima et al. 
suggests that the unmodified phosphate is cleaved in the liver 
freeing the non-conjugated ASO.115 In 2007, Moschos et al. co-
valently attached the cholesterol moiety to the oligonucleotide 
sequence via a disulfide linker that is cleaved under intracellular 
reductive conditions.116 In this study, the authors suggest that 
conjugation to cholesterol extends but does not increase siRNA-
mediated mRNA knockdown in the lung (MAP kinase mRNA 
in mouse lung). 
Squalene. Squalene is a triterpene molecule and bio-
synthetic precursor of cholesterol found in plants and animals. 
Squalene is often conjugated to the 3'-end of the sense strand of 
siRNA via a thiol-maleimide coupling. Due to the resulting am-
phiphilic character of the squalene-oligonucloetide conjugate, 
these conjugates spontaneously formed spherical assemblies of 
165 ± 10 nm diameter with a zeta potential of − 26 mV in aque-
ous media. These nanoparticles show enhanced oligonucleotide 
stability in the presence of serum and higher catalytic potency 
in vitro and in vivo against the targeted RET/PTC1 mRNA com-
pared to the unmodified siRNA. Up to 70% inhibition of the 
tumor growth is observed after 19 days following intravenous 
injections of 2.5 mg/kg modified siRNA at day 0, 2, 4, 7 and 
10.117,118 
Fatty acids. Currently in clinical trial (phase 2) for the 
treatment of myelofibrosis, GRN163L is a telomerase targeting, 
antisense oligonucleotide of thio-phosphoramidate with a cova-
lently linked palmitic acid at the 5'-end (Figure 8).119–121 The 
palmitic acid moity is conjugated though a PTO linkage to the 
backbone of the ASO. Telomerase activity is up-regulated in 
numerous cancers and, thus, is a viable target for treatment. Te-
lomere shortening and lower cell viability are observed after in-
hibition of telomerase activity in cancer cell lines. The IC50 val-
ues ranged from 50 to 200 nM for telomerase expression in 10 
 
Figure 7: Molecular structure of a photocleavable cholesterol-con-
jugated oligonucleotide, adapted from Yang J. et al. 2018111 
 
 
 
Figure 8: Molecular structure of GRN163L. The lipid oligonucleotide 
GRN163L, 5’ – Palm – TAGGGTTAGACAA – NH2 – 3’, with a 
thio-phosphoramidate inter-nucleosidic linkage (top) and its structu-
ral formula (down) from the Chemspider website. 
 different pancreatic cell lines in the presence of GRN163. Te-
lomerase reactivation and elongation are also observed when 
the antisense is no longer present, indicating that sequences tar-
geting the RNA template region of telomerase are effective in-
hibitors of telomerase. GRN163L is a potential adjuvant for 
cancer treatment as it halts the progression of the tumor by re-
storing a normal, correct phenotype for the cancerous cells. 
 The in vitro inhibition of telomerase activity by ASO 
is improved with the palmitoyle modification. An inhibition 
factor ranging from 1.4 to 39 is observed depending on the cell 
type (cervix, glioblastoma, hepatocarcinoma, lungs, melanoma, 
myeloma, ovary and prostate). In vivo efficacy (up to 56% inhi-
bition of telomerase activity after 24h compared to the uncou-
pled antisense or PBS) is also observed in a murine xenograft 
model following intravenous injection (50 mg/kg) in the ab-
sence of any additional transfecting reagent.119 Additionally, in-
vestigations reveal a synergistic effect when GRN163L is co-
administered with trastuzumab, a recombinant monoclonal an-
tibody targeting HER2+ receptors in breast cancers.121 The 
composition of the lipid (oleic vs palmitic acid in the lipid oli-
gonucleotide conjugate) was also evaluated, but with no notice-
able difference in efficacy.  
Ketal nucleolipid conjugate. Nucleolipids, first reported by our 
groups, are also being investigated.48,52 For example, the ketal 
uridine phosphoramidite with two alkyl chains at the 2’ and the 
3’ positions, anchors oligonucleotides to liposomal mem-
branes122. These lipid-oligonucleotides are amphiphilic with 
micellar aggregation properties that are used as a functional res-
ervoir for hydrophobic drugs. The drug payload of the micelles 
is released in the presence of the oligonucleotides complemen-
tary to the lipid-DNA conjugate.123 Similarly modified ASOs 
are investigated for the treatment of prostate cancer.124 An anti-
sense strategy based on targeting the Translational Controlled 
Tumor Protein (TCTP) is described for the treatment of Castra-
tion resistant prostate cancer (CRPC), a disease currently with 
a very low survival rate (median survival reported between 9 
and 30 months).125–127 TCTP is minimally expressed in healthy 
prostatic tissue, moderately in prostatic cancer cells, and over-
expressed in CRPC cells. Therefore, designing an inhibitory se-
quence is key for this promising strategy for the treatment of 
CRPC. An ASO sequence of 20 nucleotides with PTO back-
bone was selected to impede TCTP expression. Normally, this 
ASO sequence requires the assistance of a vectorization agent 
such as oligofectamine to be efficient in vitro. The conjugation 
of the ASO with the ketal nucleolipid enables the inhibition of 
TCTP in the absence of transfecting agent in vitro and in vivo.124 
Bis-conjugates. Multi-functionalized, bis-conjugated 
oligonucleotides are also being investigated. Tajik-Ahmadabad 
et al.128 designed an amphiphilic CPP-modified ASO (in the 
PMO series) capable of self-assembly. The ASO is functional-
ized by coupling a 3-maleimidopropanoic acid moiety to the 
free secondary amine group at the 3’ end. This maleimido-PMO 
was purified by HPLC method. The fatty-acid modified peptide 
was prepared by coupling myristic anhydride at the N-terminus 
of the resin-bound ApoE. After deprotection and resin cleavage, 
the ApoE peptide with C-terminal cysteine was conjugated to 
the ASO by thiol-maleimide click reaction. The spontaneous 
self-assembly of this ASO occurs when myristic acid is cova-
lently attached to the N-terminus of the peptide. The bis-conju-
gated ASO inhibits exon 7 splicing of the pre-mRNA SMN2 
gene, which is responsible for the pathology of spinal muscular 
atrophy. These amphiphilic species exhibit a 4-fold increase in 
potency relative to the CPP-ASO mono-conjugate. 
A similar approach is described by Wada et al., who 
used cholesterol and GalNac as modifiers at the 5'-end of an 
ASO targeting ApoB (Figure 9).129 The conjugation was pre-
pared using phosphoramidite chemistry, amenable to solid sup-
port synthesis of oligonucleotides. The monovalent GalNAc 
phosphoramidite used was described earlier by Yamamoto et 
al.130 Such a dual conjugation strategy reduces the renal biodis-
tribution of the oligonucleotide. In that case, the cholesterol-
conjugated ASO also possessed a 3-nucleotide-long linker with 
phosphodiester linkages susceptible to endonuclease hydrolysis 
in the targeted tissues or cells. Accumulation of the GalNac-
modified ASO is low in the kidney just like the double 5'-mod-
ified cholesterol-GalNAc ASO. Renal accumulation is five 
times lower when the ASO is modified at both extremities one 
with the lipid and the other with GalNAc. As expected, the Gal-
Nac modified ASOs preferentially accumulate in the liver. 
Thus, the cholesterol–GalNAc dual strategy represents an ef-
fective strategy for reducing the nephrotoxic potential of ASOs, 
while maintaining the gene silencing activity in the liver. 
Spherical Nucleic Acids. Spherical Nucleic Acids 
(SNAs) are a class of nucleic acid conjugates differentiated 
from other conjugates here through their three dimensional 
nanostructure131. First developed by Chad Mirkin, this structure 
is composed of oriented single or double stranded nucleic acids 
in a dense spherical array (Figure 10). First generation SNAs 
possessed a gold nanoparticle core with Au-S linkages to the 
nucleic acids, and since then have been expanded to contain 
other cores for specific applications131. SNA structures are ame-
nable to further modification to contain targeting ligands such 
as antibodies132, and immune agents such as antigens133,134. 
SNAs can also be formed with RNA135, modified backbones133, 
and sugar modifications136. SNAs exhibit increased nuclease re-
sistance due to their structure131 and are readily endocytosed137 
into cells without additional transfection making them an attrac-
tive bioconjugate class to enhance delivery137. Liposomal 
SNAs138 are formulated from 1,2-dioleoyl-sn-glycero-3-phos-
phocholine and a tocopherol-oligonucleotide conjugate which 
contains a phosphodiester linkage and a PEG spacer (discussed 
in its own section above). Tocopherol-oligonucleotide conju-
gates form micellar structures, but liposomal SNAs provide ad-
ditional benefit133. Liposomal SNA formulations are being eval-
uated as a novel therapy for immune modulation116,133,134 For 
example, SNAs are effective for both immune TLR agonism 
and inhibition through either target sequence dependent binding 
to TLR receptors or the receptor for mRNA translation133. 
Receptor agonism strategies focus on agonism 
through TLRs,133,134 and the activity of the SNA conjugates is 
dependent on linker chemistry. SNA and tocopherol oligonu-
cleotide conjugates show effective immune stimulation and tu-
 
Figure 9: Cholesterol and GalNAc coupled ASO, adapted from 
Wada F. et al. 2018 129 TEG : Triethylene glycol ; GalNAc : N-
acetylgalactosamine ; ASO : AntiSense Oligonucleotide 
 mor growth reduction in vivo,133 and SNA formulations demon-
strate the highest efficacy. In a recent publication134, a mela-
noma-specific peptide antigen was conjugated via three differ-
ent linkers to a TLR9 agonizing oligonucleotide adjuvant. The 
complimentary oligonucleotide was conjugated to an antigen. 
Three different antigen-oligonucleotide linkages were evalu-
ated: one stable (N-(β-maleimidopropyloxy) succinimide es-
ter), one cleavable (succinimidyl 3-(2-pyridyldithio)propio-
nate), and a traceless linkage (4-nitrophenyl 2-(2-pyridyl-
dithio)ethyl carbonate). See Figure 10 for structural compari-
son. The traceless linkage undergoes an internal cyclization in 
addition to a disulfide cleavage to yield the antigen’s native N-
terminus. The choice of linker conjugation significantly influ-
enced activity. The SNA formulations possessing the cleavable, 
traceless delivery linkage yielded the greatest T cell activation 
and proliferation. Importantly, these findings highlight the crit-
ical role the linker plays. Moreover, they also demonstrate the 
potential for oligonucleotide conjugates to expand to new ap-
plications and a few SNA formulations are progressing through 
preclinical into early clinical development (e.g., 
NCT03086278, Table 1 and discussion below). 139,140. 
 
OLIGONUCLEOTIDES THERAPEUTIC 
APPLICATION 
As exemplified in the preceding sections, numerous oligonucle-
otides have been investigated for a range of diseases. The ma-
jority of these bioconjugated oligonucleotides are in preclinical 
studies (i.e., in vitro and small animal in vivo efficacy studies). 
Importantly, several formulations are regulatory approved and 
used in the clinic (Table 1). The data accumulated in Table 1 
are from company web sites and the clinicaltrials.gov web re-
source. The first regulatory approved oligonucleotide (in 1998 
by the FDA and in 1999 by the EMA (European Medicines 
Agency)) was for the treatment of cytomegalovirus retina, a vi-
ral infection of the eye. If untreated, vision loss can occur in 
immune compromised patients. Specifically, Fomivirsen 
(Vitravene®) was developed by IONIS Pharmaceutical (ISIS at 
the time) in collaboration with Novartis Ophthalmics.141 This 
biomacromolecule, composed of 21 PTO nucleotides, is com-
plementary to one viral mRNA. The posology consists of a 
weekly intravitreal injection of 165 µg of a Fomivirsen solution 
at 6.6 mg/mL.142 The market authorization was withdrawn on 
July 30th 2002 at the request of the manufacturer for business 
reasons. Vitravene® is still authorized in Switzerland and can be 
administered in the European Union upon specific request. Im-
portantly, this success laid the foundation for a number of oli-
gonucleotides being ushered into commercial development and 
the reader is referred to several reviews on this topic.68,143–146  
As discussed in the introduction of this Review, the 
design of oligonucleotides for use in the clinic requires specific 
design considerations and optimizations other than improved 
delivery.147 For enhanced in vivo efficacy, oligonucleotides 
containing chemical modifications such as 2’-O-MOE, 2’OMe, 
LNA and PMO are used to protect against degradation and in-
crease target binding affinity. To date, the most common oligo-
nucleotide modifications are PTO DNA and 2’-O-MOE. Addi-
tionally, 2’OMe and LNA are used, but most of these oligonu-
cleotides are still in phase 1 or 2 clinical trials.143,148 As of 2010, 
all of the oligonucleotides approved by the FDA and in phase 3 
clinical trials contain PTO linkages.  
The selection of oligonucleotide modifications de-
fines the mechanism(s) of inhibition (Figure 2). The majority of 
oligonucleotides in phase 1 or 2 trial participate in an RNase H 
based inhibition mechanism, but are of more diverse chemical 
composition and functionalization. That said, the inhibition 
mechanisms available include intron-exon splicing, RNase H 
activation, or blockage of translation through steric hindrance. 
The following subsections are organized according to targeted 
disease with a discussion of the bioconjugated oligonucleotides 
used as well as their mechanism of action. 
 Bone Marrow disorders. (Myelofibrosis and myelo-
dysplastic disorders). Myeleofibrosis is caused by the replace-
ment of bone marrow with scar tissue. The resulting scarring 
leads to a reduction of red blood cell formation. Myelodysplas-
tic syndrome is a type of cancer in the bone marrow. Risk fac-
tors are genetic or caused by or arise during some cancer treat-
ments. Imetelstat is a palmitoyl lipid oligonucleotide conjugate 
in clinic trials to treat these diseases. This 13 nucleotide-long 
ASO targets telomerase activity, using palmitate as the target-
ing ligand, with thio-phospharamidite linkages including the 
linkage to the palmitate group (Figure 11). 
The drug has completed multiple phase II clinical tri-
als for metastatic breast cancer and multiple myeloma cancers 
patients. The dose is limited by thrombocytopenia. Imetelstat 
(GRN163L) received a fast track status in October 2017 from 
the FDA for certain patients with a myelodysplastic syn-
drome.149 
 Hepatitis B. Hepatitis B is a common liver infection. 
The genome of the hepatitis B virus (HBV) is an attractive tar-
get because there are multiple sites on the HBV genome that 
can be targeted simultaneously. There are several conjugates in 
the pipeline for the treatment of this disease. For example, 
ARC-520 is an equimolar combination of two cholesterol con-
jugated siRNAs, siHBV74 and siHBV77, targeting an 18 nucle-
 
Figure 10: Spherical Nucleic Acids. A. SNAs present nucleic 
acids in an outward facing spherical array. B. Oligonucleotide-
tocopherol conjugates form SNAs with liposomal cores. C. 
Structure of linkage and tocopherol moiety. D. TLR agonizing 
oligonucleotides conjugated to tocopherol can be combined 
with antigens through a complimentary oligonucleotide and 
chemical conjugation through a linker. E. Different conjugate 
linkage chemistries explored. 
 otide long sequence in the HBV genome. In addition to the siR-
NAs, a GalNAc conjugated peptide is included as an excipient 
to aid in delivery and endosomal escape. A Phase trial I was 
completed in 2018, but the results have not been publicized as 
of September 2018. Other clinical trials with ARC-520 have 
been withdrawn/terminated, likely due to the difficulty in 
knocking down expression due to HBV DNA integrated into the 
host genome. Arrowhead Pharmaceuticals has a combined 
phase I/II clinical trial currently recruiting for ARO-HBV. Al-
nylam terminated a phase I clinical trial using ALN-HBV01, a 
23 nucleotide long, GalNAc conjugated, siRNA. This GalNAc 
conjugated siRNA incorporated numerous modifications for 
solubility and stability, including 2'-F, 2-OMe, with PS linkages 
only near the siRNA termini. The discontinuation is part of a 
new agreement with Vir Biotechnology to begin development 
on ALN-HBV02, also a GalNAc conjugate, citing reduced off 
target effects due to the incorporation of glycol nucleic acids 
(GNAs) in the backbone. 
 Hemophilia. Hemophilia is a blood clotting disorder. 
Fitusiran (ALN-AT3sc) is a GalNAc conjugate targeting an-
tithrombin currently entering phase III clinical trials. In a phase 
I study, the mean antithrombin (AT) knockdown was reported 
to be 59%. The study included 4 healthy volunteers (A) and 12 
patients with severe hemophilia (B). In one hemophilia patient, 
a maximal knockdown of 86% was reported along with 114 
days bleed free. This conjugate was administrated via subcuta-
neous injection. First phase results showed the reduction of lev-
els of the antithrombin protein and the restoration of the balance 
for the production of clotting factors in adult A and hemophilia 
B patients, after a single monthly injection. The second phase 
of the trial was suspended because one hemophilia A patient 
died due to a cerebral edema. The suspension of the clinical trial 
was lifted after the trial’s protocol was amended to better miti-
gate risks. Alnylam and Sanofi are scheduled to conduct a phase 
3 clinical trial in 2018/2019 with the ATLAS program,150 which 
will include patients with hemophilia A and B with or without 
inhibitors, and patients previously receiving on-demand or 
prophylactic therapy. 
 Psoriasis. Psoriasis is a chronic skin disease where 
skin cells undergo a rapid cell cycle. SNAs are being developed 
to treat dermatologic indications such as mild to moderate Pso-
riasis139,140. Recently completed results from Phase I studies for 
IL17RA and TNFα protein targets are promising (Purdue 
Pharma). The SNAs are absorbed through the skin and deliver 
siRNAs into the epidermis139 providing effective knockdown of 
targets within keratinocytes with minimal immune response. 
Topical administration offers a local treatment option, which 
minimizes systemic off-target effects. 
Cancer. Cancer is the unwanted abnormal growth and 
invasion of cells in the body. Of the various treatment classes – 
surgery, radiation, chemotherapy, and immunotherapy – immu-
notherapy is a particularly exciting one as it provides a means 
to use the immune system to fight the disease. For example, ac-
tivation of Toll-like receptor 9 (TLR9) initiates a cascade of in-
nate and adaptive immune responses including increased inter-
feron gene expression. Increased interferon gene expression 
correlates with improved responses to programmed death 1 
(PD-1) inhibition. Thus, patients who did not respond or 
stopped responding to anti–PD-1 therapy are potential candi-
dates for combined TLR9 agonists and anti–PD-1 therapy. Ex-
icure has successfully completed a Phase I trial of TLR9 ago-
nizing SNAs administered subcutaneously in healthy volunteers 
(NCT03086278). A Phase Ib/II study is planned to study intra-
tumorally delivered SNAs both alone and in combination with 
intravenously administered pembrolizumab, an antibody target-
ing the PD-1 receptor. The target cohort is in patients that have 
not yet responded to anti-PD-1 or anti-PD-L1 therapies 
(NCT03684785). 
 
 
Figure 11: Structure of the thio-phospharamidite based ASO with 
a telomerase activity. The targeting moiety (palmitate) has been 
inserted at the 3’ extremity.  
 
  Age-Related Macular Degeneration. Age-related 
Macular Degeneration (ARMD) is the gradual worsening of vi-
sion and eye health over time due to retina damage. The blurring 
or loss of vision associated with ARMD is characterized by the 
proliferation of blood vessels behind the retina. In "wet" macu-
lar degeneration, neovascularization can worsen symptoms and 
is activated by Vascular Endothelial Growth Factor (VEGF) 
signaling. Macugen® (Pegaptanib) is a 27-nucleobase aptamer 
Table 1. Bioconjugate oligonucleotides in the clinic. 
Name Target Linker Moiety stage Trial Reference 
APOC-III-L-Rx apoC-III   GalNAc3 ii recriuting NCT03385239 
ARC-520 HBV   Cholesterol multiple i/ii NCT01872065 
DCR-PHXC-101 GO   GalNAc i recruiting NCT03392896 
FXI-LRx Factor XI 2'-MOE GalNAc i recruiting NCT03582462 
Inclisiran (ALN-PCSSC) PCSK9   GalNAc multiple i/ii/iii NCT03397121 
Macugen VEGF   PEG Approved   
Zimura (Avacincaptad 
pegol) C5   PEG iib NCT03374670 
Fovista (E10030) PGDF   PEG terminated NCT01944839 
Imetelstat Sodium 
(GRN163L) telomerase thio-phosphoramidite Palmitate ii NCT01731951 
Revusiran (ALN-TTRSC) TTR-FAC   GalNAc discontinued   
Fitusiran (ANL-AT3sc) antithrombin   GalNAc iii recruiting NCT03549871 
Cemdisiran (ALN-CC5) Complement C5   GalNAc ii recruiting NCT03303313 
Givosiran (ALN-AS1) ALAS1   GalNAc iii active NCT03338816 
Lumasiran (ALN-G01) GO   GalNAc ii enrolling NCT03350451 
ALN-HBV HBV   GalNAc i terminated NCT02826018 
ALN-AAT 
alpha-1antitrypsin 
PiZZ allele   GalNAC i/ii terminated NCT02503683 
RG-101 HCV   GalNAc terminated   
ALN-TTRSC02 TTR   GalNAc i completed NCT02797847 
Akcea-APO(a)-L_rx apoC-III 2'-O-(2-methoxyethyl) GalNAc ii active NCT03070782 
IONIS-AGT-LRx AGT 5-10-5 MOE gapmer GalNAc i completed NCT03101878 
IONIS-ANGPTL3-LRx ANGPTL3 
Phosphtiorate and Phos-
phodiester GalNAc ii NCT03371355 
IONIS-TMPRSS6-LRx TMPRSS6   GalNAc i NCT03165864 
ARO-HBV HBV     i/ii, recruiting NCT03365947 
IONIS-PKK-LRx PKK     i recruiting NCT03263507 
IONIS-GHR-LRx GHR     ii recruiting NCT03548415 
IONIS-AZ4-2.5-LRx undisclosed     i recruiting NCT03593785 
AMG-890 
cardiovascular dis-
ease     i recruiting NCT03626662 
ARC-AAT AAT   Cholesterol ii, withdrawn NCT02363946 
AST 008 TLR9  
Spherical 
Nucleic 
Acids i completed NCT03086278 
AST 008 and Pembroli-
zumab i TLR9  
Spherical 
Nucleic 
Acids i planned NCT03684785 
XCUR17 IL17RA and TNFα  
Spherical 
Nucleic 
Acids i completed  
 
 targeting VEGF165 binding,
151,152 and possesses a 3’-3’ deoxy-
thymidine extremity and a 5’end with two branched polyeth-
ylene glycol chains of 20 kDa. The 2’ positions are modified for 
nuclease resistance purposes by 2’OMe for bases purines and 
fluorinated pyrimidines (Figure 12). Importantly, the aptamer 
binds the heparin site of VEGF with a picomolar affinity. The 
FDA approved this aptamer for the treatment of "wet" or Age-
Related Macular Degeneration. Specifically, Macugen®, in-
jected intravitreally, locally reduces the proliferation/expansion 
of blood vessels and a lack of adverse events is still observed at 
a dose ten times higher than clinically used. The product is 
available in the form of pre filled syringes of 90 µL solution 
containing 0.3 mg of active substance. 
Several other drugs have been developed for the treat-
ment of ARMD. In the EU, Lucentis® (ranibizumab, Novartis), 
a monoclonal antibody fragment that targets VEGF, and Eylea® 
(aflibercept, Bayer) a recombinant fusion protein that binds to 
VEGF-A, VEGF-B, and placental growth factor (PIGF) with 
higher affinity than their native receptors. Avastin® (bevaci-
zumab, Roche) is a humanized recombinant monoclonal anti-
body that binds VEGF and competitively inhibits the binding 
between VEGF and Flt-1 and KDR. It adds to the list of 
Macugen® competitors in the United States. The other nucleic 
acid treatment for ARMD is a modified siRNA called beva-
siranib. It is a duplex of a 21-nt long RNA that targets VEGF.153 
Bevasiranib has not been approved but shows efficacy when 
combined with Lucentis® in clinical trials.148 The effects of 
bevasiranib appear only six weeks after the beginning of the 
treatment, but the combination of Lucentis®/bevasiranib pro-
vides better visual acuity than Lucentis® alone. 
 Hepatic Porphyrias. These conditions are a combina-
tion of rare diseases that all overlap in that they all feature the 
accumulation of porphyrins in the blood. The build-up of these 
proteins causes nervous or dermatological symptoms. Currently 
in an ongoing phase III clinical trial, Givosiran (ALN-AS1), is 
a GalNAc conjugate siRNA targeting aminovulinate synthase 1 
(ALAS1) present in the liver. In a Phase I trial with 23 patients, 
11 patients reported mild or moderate adverse events (AE) with 
1 reporting an unrelated, severe AE of abdominal pain and an-
other reported unrelated AE of bursitis. Common mild/moder-
ate AEs of abdominal pain, diarrhea, nasopharyngitis, and hy-
poesthesia, pruritus, and rash were noted, but were not serious 
enough to stop treatment. The product was injected by single or 
multiple subcutaneous injections and compared to an injection 
of sterile normal saline solution. The purpose of the next phase 
1 trial was to evaluate the safety and tolerability of Givosiran 
(ALN-AS1) in Acute Intermittent Porphyria (AIP) patients as 
well as to characterize pharmacokinetics (PK) and pharmaco-
dynamics (PD) of ALN-AS1 in AIP patients. The safety and 
efficacy of Givosiran was evaluated in 17 patients with acute 
AIP. The patients were initially monitored for three months and 
those who experienced one porphyria attack were eligible to re-
ceive once monthly injections of 2.5 or 5.0 mg/kg Givosiran or 
placebo for six months. Durable inhibition of ALAS1 was ob-
served after Givosiran treatment. The lower tested dose of 2.5 
mg/kg reduced the annualized attack rate by 83% and afforded 
a reduction of 88% of hemin compared to the placebo. A larger 
dose did not produce any amelioration. In 2018, data showed 
that at 22 months of therapy, patients were still experiencing a 
robust beneficial effect from Givosiran. 
 Famyloid polyneuropathy. Familial Amyloid Poly-
neuropathy (FAP) is a genetic autosomal dominant disorder re-
sulting from a mutation of the TTR (transthyretin) gene, leading 
to TTR protein aggregation, which negatively affects the nerv-
ous system. Oligonucleotide therapeutic agents designed for the 
treatment of FAP, also known as Transthyretin-related heredi-
tary amyloidosis (ATTR), target the mRNA sequence of trans-
thyretin (TTR) for degradation. Three formulations are in clin-
ical trials to decrease expression of TTR: Inotersen (developed 
by Ionis and GSK), Onpattro (Patisiran developed by Alnylam), 
and Revusiran (developed in collaboration between Alnylam 
and Sanofi Genzyme).154 These therapeutics (2 siRNAs -one be-
ing a GalNac conjugate- and an ASO) are in phase 3 clinical 
trials. One study compared the inhibitory activity of Inotersen 
(ASO) and Patisiran (siRNA). Both treatments led to a 80% de-
crease in TTR expression.155 Inotersen (IONIS-TTRRx),
156 is a 
20-nucleotide long gapmer PTO ASO with 5 2’-O-MOE modi-
fications at both extremities. The ASO targets pre-mRNA that 
is degraded following RNase H activity.157 Inotersen sodium is 
subcutaneously injected weekly at a dose of 300 mg (284 mg of 
inotersen). Of note, three cases (out of the 172 patients tested 
over 64 weeks) reported thrombocytopenia. Inotersen has re-
ceived marketing authorization approval from the European 
Commission (EC) for the treatment of stage 1 or stage 2 poly-
neuropathy in adult patients with hereditary transthyretin amy-
loidosis (hATTR). Inotersen is commercialized under the name 
of Tegsedi™. 
 Patisiran (ALN-TTR02, Onpattro™) is an advanced 
siRNA under development and is administered intravenously as 
lipidic nanoparticles (LNP) at noticeably low doses of 
0.3 mg/kg every three weeks over an 18-month period. The 
most common adverse events observed in patients were periph-
eral edema and infusion related reactions.148,158 In August 2018, 
Patisiran received U.S. Food and Drug (FDA) approval for the 
treatment of the polyneuropathy of hereditary transthyretin-me-
diated amyloidosis in adults. Regulatory filings in other mar-
kets, including Japan, are planned. The European Commission 
also granted marketing authorization for Onpattro™ on August 
30th, 2018. 
 Revusiran. a GalNac siRNA conjugate administered 
subcutaneously, was previously undergoing phase 3 clinical tri-
als. This molecule has two PTO linkages, 22 2’-OMe nucleo-
tides, and another 22 modified residues with 2’F modifications. 
However, development was stopped due to numerous AEs lead-
ing to deaths in phase 3 clinical studies. Causes of theses side 
 
Figure 12: Secondary structure of Pegaptanib, active substance of Ma-
cugen® Adapted from Ng E. W. M. et al. 2006 152 
 effects have not been published but the high weekly dose of 500 
mg was suspected. 
 Historic timeline of developments 
 There have been numerous developments over the 
past 50 years that have led to the clinical efficacy of oligonu-
cleotides for treating diseases.159 The timeline featuring signifi-
cant accomplishments is presented in figure 12. ASOs were the 
first oligonucleotides to reach clinical trials and to receive reg-
ulatory approval. Notably, this conjugated (pegylated) aptamer 
has been in use for more than 14 years. The development of 
siRNA therapeutics advanced significantly in the early 2000s 
and their first use in humans occurred in 2005 (bevasiranib). 
siRNA therapeutics that functioned as splicing modulators fol-
lowed next in development and commercialization. Antagomirs 
(miRNA inhibitors) were developed in 2009 and were followed 
by miRNA mimetics in 2013. These two former classes of oli-
gonucleotides utilize miRNAs to modulate the activity of a 
given gene. For example, Miravirsen sequesters microRNA-
122 and is used for the treatment of chronic hepatitis C,160,161 
whereas mimics of microARN-34a exhibit potentiated anti-
tumor activity. Over 30 oncogenes are known to be inhibited by 
this microRNA.162 
 
6. FUTURE OPPORTUNITIES AND CONCLUSION  
Several bioconjugated oligonucleotides are regulatory ap-
proved and used in the clinic. These bioconjugates possess a 
carbohydrate (Patisiran), a polymer (Pegaptanib), or a lipid 
(Imetelstat - GRN163L, currently on fast track status) cova-
lently linked to the oligonucleotides. A number of additional 
ones are in preclinical development as well as clinical studies 
(see Table 1.). The primary function of these added conjugates 
is to enhance targeting, facilitate vectorization, reduce oligonu-
cleotide susceptibility to nuclease activity, eliminate or reduce 
need for toxic transfection agents, and generally improve phar-
macological activity and efficacy. Increasing the therapeutic 
window and reducing the likelihood for adverse events is a top 
priority, and the use of conjugated oligonucleotides is an effec-
tive approach. As discussed above, these conjugates are lipo-
philic or a targeting moiety.  
Most of the therapies currently in late-stage develop-
ment target the liver and liver associated diseases. This is 
largely due to the success of the GalNAc modification, and the 
fact that the liver is an efficient filter for the blood. Other highly 
efficient targeting moieties need to be developed to target other 
organs or tissues – lung, kidney, heart, bone marrow, brain, 
muscle, etc. Poor delivery to target sites necessitates higher 
doses, decreasing safety with greater chances of AEs. One strat-
egy to reduce the severity of AEs is to modulate or knockdown 
the effect after administration. For example, a single subcutane-
ous 3 mg/kg GalNAc-siRNA dose can be effectively reversed 
with a 0.1 mg/kg GalNAc oligonucleotide conjugate targeting 
the seed region of the incorporated siRNA strand163. The result 
demonstrates both effective knockdown and return of TTR pro-
tein levels in preclinical in vivo studies. The evolution of safe 
antidotes for oligonucleotide therapies, such as the REVERSIR 
strategy reported by Zlatev et al., poses benefits for safety and 
adoption into the clinic.164 The possibility to finely control 
RNAi pharmacology is a desired feature for highly efficient nu-
cleic based therapeutic treatments. 
 At the molecular level, advances in oligonucleotide 
chemistry are providing new methods and site-specific reac-
tions to modify oligonucleotides at the base, sugar, phosphate, 
or end groups. Additionally, natural bases can be substituted 
 
Figure 13: Timeline for Key Advances in Therapeutic Oligonucleotides. Adapted from Lundin K. E. et al. 2015 159 The various substitutions and 
the advances of chemical modifications are shown in yellow, main discoveries and technological achievements are noted in blue and clinical 
studies are highlighted in green. 
 
 with synthetic analogs. These developments afford a large di-
versity of new and unique biomacromolecules. Still, significant 
opportunities exist in this area to improve on reaction effi-
ciency, to expand on the compositional diversity of modifica-
tions, and to realize structure-property relationships for na-
noscale, self-assembling, and supramolecular systems. These 
improvements will allow for more modular, diverse, and effec-
tive formulations. Similarly, molecular biology studies are 
providing new therapeutic targets with an improved under-
standing of pathways and resulting pathologies. As such, the 
development of combination therapies is forthcoming. The pos-
sible combinations will target either one or multiple mRNAs or 
combine a bioconjugated oligonucleotide with a small molecule 
or protein in order to improve efficacy and safety profiles. 
 As discussed in this review, modifications such as 
GalNAc, cell penetrating peptides, α-tocopherol, aptamers, an-
tibodies, cholesterol, squalene, fatty acids, and nucleolipids are 
new promising therapeutic candidates in the field. Despite the 
clinical progress to date, the design of modified oligonucleo-
tides encompassing both the optimal delivery and efficient bio-
logical activity remains an important challenge. Diseases such 
as coronary heart disease, lower respiratory infections, cancer, 
diabetes, and Alzheimer’s are in need of new therapies, and, as 
oligonucleotides can target and bind nearly any expressed 
mRNA, the possibility to develop oligonucleotide therapeutics 
exist. Key to these future successes will be understanding the 
pharmacokinetic and biodistribution profiles of these new ther-
apeutics. Despite the promising bioconjugated oligonucleotides 
reported so far, oligonucleotide delivery represents a major hur-
dle still to be addressed. As mentioned previously, most of the 
oligonucleotide conjugates used in clinic bio-accumulate in the 
liver. Furthermore, a clear relationship between the composi-
tion and structure of the chemical modification and its resulting 
effect on pharmacokinetic/biodistribution must be both quanti-
fied and established with appropriate positive and negative con-
trols in place. For example, membrane interacting bioconju-
gates often interact with many targets and are known for their 
promiscuity. Such a molecular rationale would allow scientists 
to design the chemical structure of the oligonucleotides depend-
ing on the specific disease, target tissue/organ, cell type etc. 
 In summary, the use of oligonucleotides in the clinic 
is in its infancy and the potential for significant advances in pa-
tient care exist. Given the clinical success of monoclonical an-
tibodies (mAb) as a biologic, we speculate that oligonucleotides 
will have a greater impact due to the specificity inherent to the 
target sequence, the ability to target nearly any protein, and their 
stability both pre-administration and in vivo. The full realization 
and maturation of the bioconjugated oligonucleotide therapeu-
tic field will require time – e.g., 19 mAb drugs were on the mar-
ket only after 20 years of development – but this should not cur-
tail enthusiasm. In fact, findings from these mAb studies as well 
as from polymer conjugated enzymes and small molecules used 
in the clinic will catalyze development and subsequent clinical 
applicability.165 Bioconjugation chemistry is at the centerpiece 
on this therapeutic oligonucleotide revolution. We encourage 
all to investigate this area where conceptualizing, designing, 
and engineering at the molecular level new functionalized oli-
gonucleotides is key to success in the clinic.  
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